RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
Condition(s):Non-Muscle Invasive Bladder Cancer; HER2Last Updated:August 31, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Non-Muscle Invasive Bladder Cancer; HER2Last Updated:August 31, 2023Recruiting
Condition(s):Non-muscle Invasive Bladder Cancer (NMIBC)Last Updated:August 19, 2020Terminated
Condition(s):Bladder CancerLast Updated:August 4, 2023Active, not recruiting
Condition(s):Hematuria; Dysuria; Bladder CancerLast Updated:September 24, 2015Unknown status
Condition(s):Non Muscle Invasive Bladder CancerLast Updated:February 22, 2024Active, not recruiting
Condition(s):Non Muscle Invasive Bladder CancerLast Updated:August 24, 2022Active, not recruiting
Condition(s):Bladder CancerLast Updated:September 28, 2021Terminated
Condition(s):Overactive BladderLast Updated:October 26, 2015Terminated
Condition(s):Chronic Interstitial Cystitis; Bladder Pain Syndrome; Painful Bladder Syndrome; Cystitis, Interstitial; Cystitis, Chronic Interstitial; Interstitial Cystitis; Interstitial Cystitis, Chronic; Interstitial Cystitis (Chronic) With Hematuria; Interstitial Cystitis (Chronic) Without Hematuria; Chronic Prostatitis; Chronic Prostatitis With Chronic Pelvic Pain SyndromeLast Updated:March 8, 2024Not yet recruiting
Condition(s):Overactive Bladder (OAB)Last Updated:January 27, 2021Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.